Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy

Author(s): Kaniyampadi S. Snima, Prathesha Pillai, Aleena M. Cherian, Shantikumar V. Nair, Vinoth-Kumar Lakshmanan

Journal Name: Current Cancer Drug Targets

Volume 14 , Issue 8 , 2014

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Metformin, a biguanide, is a commonly administered drug for the management of type 2 diabetes mellitus. The drug received tremendous recognition, when retrospective studies proved metformin-associated reduction in cancer risk. Metformin has potential anticancer effects and an ability to suppress tumor growth both in vitro and in vivo. Activation of LKB1/AMPK pathway and cancer stem cell destruction along with cell cycle arrest and apoptosis induction are the proposed mechanisms of anticancer potential of metformin. Nanotechnology approaches have also been adopted for metformin delivery to cancer cells. This review directs on the application of metformin for the therapy of various cancers and also the different pathways responsible for the metformin derived anticancer effect. It also focuses on the pharmacological applications of metformin and the nanotechnology approaches for metformin delivery.

Keywords: Breast cancer, endometrial cancer, metformin, nanotechnology, prostate cancer, ovarian cancer, pancreatic cancer, pathways.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 24 November, 2014
Page: [727 - 736]
Pages: 10
DOI: 10.2174/1568009614666141020105502
Price: $65

Article Metrics

PDF: 79